To include your compound in the COVID-19 Resource Center, submit it here.

Xarelto rivaroxaban: Phase III data

The double-blind, double-dummy, international Phase III MAGELLAN trial in 8,100 hospitalized patients with acute medical illnesses showed that short- (10 days) and long-term (35 days) once-daily 10 mg oral rivaroxaban met the co-primary efficacy endpoints of non-inferiority and superiority, respectively, to once-daily 40 mg subcutaneous enoxaparin

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers